SGM-101

SGM-101 is a monoclonal antibody developed by Surgimab. Its target is CEACAM5 (the sponsor names CEA (carcinoembryonic antigen)). The sponsor states: A fluorochrome-labelled anti-CEA monoclonal antibody used as an intraoperative near-infrared imaging agent to delineate primary and recurrent tumour and metastases during surgery. ClinicalTrials.gov describes the intervention as: A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT03659448 (Performance of SGM-101 for the Delineation of Primary and Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer), in colorectal cancer. The largest, NCT03659448, plans to enrol 300 participants with primary completion expected 2024-11. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.